Brainstorm cell therapeutics announces third quarter 2024 financial results and provides corporate update

Conference call planned for later in q4 2024 to provide updates on nurown® program new york , nov. 14, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended september 30, 2024 and provided a corporate update. "brainstorm's primary focus continues to be preparing for the upcoming phase 3b registration trial of nurown in als," said chaim lebovits, president and ceo of brainstorm.
BCLI Ratings Summary
BCLI Quant Ranking